Search Result

Results for "

Kir6.2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Endogenous Metabolite (3) Parasite (1) Potassium Channel (16)
By Research Areas:	Cardiovascular Disease (5) Infection (1) Metabolic Disease (12) Neurological Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106577

Cibenzoline Cifenline; Ro 22-7796	Potassium Channel	Cardiovascular Disease
Cibenzoline is a potent inhibitor of KATP channel with directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline is a class Ia antiarrhythmic agent. Cibenzoline has little anticholinergic activity. Cibenzoline markedly attenuate LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for the research of hypertrophic obstructive cardiomyopathy .

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with *Kir6.2* .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Endogenous Metabolite Potassium Channel	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with *Kir6.2* .

HY-119322

Tifenazoxide NN414	Potassium Channel	Metabolic Disease
Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ^ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .

HY-124424

VU0071063	Potassium Channel	Others Neurological Disease
VU0071063 is a potent and specific *Kir6.2/SUR1* opener (EC₅₀=7.44 μM) and can be used for investigating *Kir6.2/SUR1* expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships .

HY-B0682

Mitiglinide KAD-1229 free acid anhydrous; S21403 free acid anhydrous	Potassium Channel	Metabolic Disease
Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-17398

Mitiglinide calcium KAD-1229 anhydrous; S21403 anhydrous	Potassium Channel	Metabolic Disease
Mitiglinide Calcium (KAD-1229 anhydrous), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes .

HY-B0682A

Mitiglinide calcium hydrate KAD-1229; S-21403	Potassium Channel	Metabolic Disease
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K_ATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K_ATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-B0682S2

Mitiglinide-d5 calcium	Potassium Channel	Metabolic Disease
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S1

(2R)-Mitiglinide-d5 calcium	Potassium Channel	Metabolic Disease
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-108573

P-1075 1 Publications Verification	Potassium Channel	Cardiovascular Disease
P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-K_IR6), with an EC₅₀ value of 45 nM for SUR2B-K_IR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .

HY-B0682S

Mitiglinide-d8 calcium hydrate	Potassium Channel	Metabolic Disease
Mitiglinide-d₈ (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].

HY-134320

8-Azido-ATP 8-Azidoadenosine 5'-triphosphate; 8-N3-ATP	Potassium Channel	Metabolic Disease
8-Azido-ATP, a photoreactable nucleotide analog, is useful for the identification of proteins, such as DNA-dependent RNA polymerase . 8-Azido-ATP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-134320B

8-Azido-ATP trisodium 8-Azidoadenosine 5'-triphosphate trisodium; 8-N3-ATP trisodium	Potassium Channel	Metabolic Disease
8-Azido-ATP (8-N3-ATP) trisodium, a photoreactable nucleotide analog, is useful for the identification of proteins, such as DNA-dependent RNA polymerase. 8-Azido-ATP trisodium is a click chemistry reagent that contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. 8-Azido-ATP trisodium can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups .

HY-118607

VU041	Potassium Channel Parasite	Infection
VU041 is a first submicromolar-affinity inhibitor of *Anopheles (An.) gambiae* and Aedes (Ae.) aegypti inward rectifier potassium 1 (Kir1) channels with IC₅₀ values of 2.5 μM and 1.7 μM, respectively. VU041 inhibits appreciably is mammalian *Kir2.1* (IC₅₀ of 12.7 μM), and has less inhibitory effect on mammalian Kir1.1, Kir4.1, Kir6.2/SUR1, and Kir7.1. VU041 also induces impaired Malpighian tubule function .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with *Kir6.2* .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Potassium Channel
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with *Kir6.2* .

Cat. No.	Product Name	Chemical Structure

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

L-Palmitoylcarnitine-d3 hydrochloride

L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-B0682S2

Mitiglinide-d5 calcium
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S1

(2R)-Mitiglinide-d5 calcium
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes[1][2].

HY-B0682S

Mitiglinide-d8 calcium hydrate
Mitiglinide-d₈ (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].

Mitiglinide-d8 calcium hydrate

Mitiglinide-d₈ (calcium hydrate) (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].

8-Azido-ATP 8-Azidoadenosine 5'-triphosphate; 8-N3-ATP		Azide
8-Azido-ATP, a photoreactable nucleotide analog, is useful for the identification of proteins, such as DNA-dependent RNA polymerase . 8-Azido-ATP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks